1. Home
  2. TOPS vs SXTP Comparison

TOPS vs SXTP Comparison

Compare TOPS & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

N/A

Current Price

$2.15

Market Cap

2.2M

ML Signal

N/A

Logo 60 Degrees Pharmaceuticals Inc.

SXTP

60 Degrees Pharmaceuticals Inc.

N/A

Current Price

$0.50

Market Cap

1.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TOPS
SXTP
Founded
2000
2010
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
1.8M
IPO Year
2004
2023

Fundamental Metrics

Financial Performance
Metric
TOPS
SXTP
Price
$2.15
$0.50
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $3.70
AVG Volume (30 Days)
303.3K
★ 307.4K
Earning Date
09-16-2026
11-16-2026
Dividend Yield
★ 35.44%
N/A
EPS Growth
N/A
★ 36.77
EPS
★ N/A
N/A
Revenue
N/A
★ $1,005,471.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$70.00
P/E Ratio
$2.14
★ N/A
Revenue Growth
N/A
★ 65.49
52 Week Low
$0.26
$0.34
52 Week High
$7.40
$8.62

Technical Indicators

Market Signals
Indicator
TOPS
SXTP
Relative Strength Index (RSI) 63.71 32.36
Support Level $0.59 N/A
Resistance Level $2.31 $1.01
Average True Range (ATR) 0.31 0.08
MACD 0.06 -0.01
Stochastic Oscillator 53.44 7.13

Price Performance

Historical Comparison
TOPS
SXTP

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco-tanker vessels, focusing on the transportation of crude oil, petroleum products (both clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements. The company operates in two reportable segments: (i) the tanker segment and (ii) the megayacht segment.

About SXTP 60 Degrees Pharmaceuticals Inc.

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Share on Social Networks: